A NASDAQ-listed clinical-stage biotechnology company is trading sharply lower today despite presenting an updated, largely positive pipeline outlook, a reaction that runs counter to what would typically be viewed as encouraging news. Sana Biotechnology (NASDAQ:SANA) management presented at the Wells Fargo Healthcare Conference, with …
A NYSE-listed medical device company is trading sharply lower today, hitting a new 52-week low, despite having beatenEarningsestimates in its most recent quarter, a reaction that runs counter to what would typically be viewed as positive news. Stryker (NYSE:SYK), speaking through CFO Preston Wells …
A Form 4 filed on September 8, 2026, with the U.S. Securities and Exchange Commission reports that John A. Carroll, VP and Chief Accounting Officer of Waste Management Inc (NYSE:WM), disposed of 1,365 shares of common stock on September 4, 2026.
Mark Dorfman, Executive Vice President, General Counsel, and Secretary of Leonardo DRS, Inc. (NASDAQ:DRS), filed a Form 4 on September 8, 2026, reporting the sale of 7,471 shares of common stock on September 4, 2026.
A Form 4 filed with the SEC on September 8, 2026, reported that Gordon Hunter, a director of Littelfuse Inc /DE (NASDAQ:LFUS), acquired a total of 8 shares of common stock on September 3, 2026, through two separate dividend-related transactions.
Kristina A. Cerniglia, a director at Littelfuse Inc /DE (NASDAQ:LFUS), filed a statement of changes in beneficial ownership on September 8, 2026, disclosing a common stock acquisition dated September 3, 2026.
Sohail Prasad, President and CEO of Destiny Tech100 Inc., filed a Form 4 on September 8, 2026, disclosing three open-market purchases of common stock totaling 56,000 shares between September 1 and September 3, 2026.
A NASDAQ-listed biotechnology company is trading sharply lower today despite raising its full-year guidance following a strong quarter, an outcome that would typically be read as good news for the stock. BioCryst Pharmaceuticals (NASDAQ:BCRX) is underperforming the broader healthcare sector even after reporting a …
A NASDAQ-listed clinical-stage biotechnology company is trading lower today despite presenting durable clinical data for its lead gene-editing program, a reaction that runs counter to what would typically be viewed as positive news. Beam Therapeutics (NASDAQ:BEAM) presented updated Phase 1/2 data for BEAM-302, its …
Compass Pathways (NASDAQ:CMPS) shares are rallying alongside a broad, sector-wide surge in biotechnology stocks, with peers including Roivant Sciences (NASDAQ:ROIV), up 17.7%, and Soleno Therapeutics (NASDAQ:SLNC), up 10%, also posting sharp gains despite limited company-specific news across the sector today. Compass is a clinical-stage …